This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Inge van de Walle
Senior Scientist at Argenx


After obtaining a Master of Science in Molecular Biology and Biotechnology, I extensively studied the role of Notch during human T cell development to obtain my PhD as Doctor in Medical Science in 2011 at the University of Ghent, Belgium. Thereafter, I worked 5 years as postdoc defining the molecular network responsible for human T cell development at the Lab of experimental Immunology (University of Ghent, Belgium). As a results I have more than 20 publication in high impact journals (like blood, nature immunology). In 2016 I joined argenx as a scientist immunology to work on a I/O antibody targeting GARP-TGFb, this antibody is now being investigated by AbbVie for the treatment of cancer. In September 2018 I became the lead scientist of the C2 program, responsible for indication selection, generation of pre clinal data and we are now heading toward our first-in-human healthy volunteers study.

Agenda Sessions

  • ARGX-117, an Inhibitory C2 Antibody with Sweeping Properties Leading to Sustained In Vivo Activity

    On Demand
  • Novel Non-cancer Targets for Therapeutic Antibodies